Previous 10 | Next 10 |
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the...
Achieve Life Sciences, Inc. (ACHV) Q4 2020 Earnings Conference Call March 11, 2021, 16:30 ET Company Participants Jaime Xinos - EVP, Commercial John Bencich - CEO & Director Jerry Wan - Senior Director, Accounting Operations & Principal Accounting Officer Cindy Jacobs - President &...
Achieve Life Sciences (ACHV): Q4 GAAP EPS of -$1.11 beats by $0.14.Cash and equivalents of $35.9M at December 31, 2020.Shares -1.7% AH.Press Release For further details see: Achieve Life Sciences EPS beats by $0.14
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth qua...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it w...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three ...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced ...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Execu...
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option SEATTLE and VANCOUVER, B.C. , Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage p...
Achieve Life Sciences Announces Pricing of $15 Million Public Offering SEATTLE and VANCOUVER, B.C. , Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerci...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today ann...
2024-05-27 04:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-17 13:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...